Guides
GMP, cell banking & quality — explained
Good Manufacturing Practice controls how applicable medicines are manufactured and documented. GMP is important, but it is not product authorisation, proof of efficacy or a certificate for an entire clinic.
GMP requirements are designed to ensure that medicinal products are consistently manufactured and controlled to the quality standards appropriate to their intended use. The applicable rules depend on the product and regulatory route.
For an ATMP, manufacturing controls may address starting materials, premises, personnel, contamination control, validated processes, testing, batch release, storage, transport, deviations and traceability. The exact specifications are product-specific.
A GMP certificate relates to an inspected manufacturing site and scope; it does not mean every product made there is authorised or suitable for every condition. Ask for the site name, address, authorisation and product-relevant scope.
The official EudraGMDP database contains manufacturing and import authorisations, GMP certificates and non-compliance statements supplied by EEA competent authorities. Questions about a record should be taken to the relevant authority.
Do not confuse a healthcare facility, a manufacturer, a testing laboratory and a sponsor. They may be different legal entities with different authorisations and responsibilities.
GMP does not determine whether clinical benefits outweigh risks. Marketing authorisation or an authorised trial separately evaluates the product, indication and evidence; a national hospital exemption also has its own conditions.
A certificate of analysis can report batch tests, but it is not a universal safety certificate. Ask which specifications were justified for identity, purity, viability, potency, sterility or other relevant attributes and who authorised release.
Donor eligibility, infectious-disease testing, procurement, transport and traceability may be governed by additional rules. A sterility result does not replace those controls or eliminate all procedural risks.
Cryopreservation and storage require validated, product-specific procedures and monitoring. A commercial cell-banking offer should be assessed through its legal basis, contract, traceability, release criteria and contingency plan, not by price.
An independent laboratory result can add information only if the method, sample, accreditation or authorisation and chain of custody are appropriate. Independence alone does not validate an unsuitable assay.
Terms such as closed system, minimal manipulation or same-day processing do not by themselves decide ATMP classification or remove regulatory duties. Classification depends on the actual processing, intended function and use.
The hospital exemption is not a general alternative to GMP or marketing authorisation. It is a narrow national route for a custom-made, non-routine ATMP used in a hospital in the same Member State under specified responsibility and controls.
International GMP frameworks are related but not interchangeable in every detail. Verify the authority and legal route for the country where manufacture and administration occur, including import requirements where relevant.
Bottom line: GMP evidence is one part of product-quality verification. Also confirm exact product identity, indication, manufacturing authorisation, regulatory route, clinical evidence, consent and follow-up; no single badge can replace that chain.
Use the cost worksheet, then verify the exact product, evidence, legal route and written quotation with an independent qualified clinician.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Educational guide; most uses are investigational. Verify the exact product, indication and provider with current regulator records and an independent qualified physician.